This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eberhard, A. Articles by Augustin, H. G. Search for Related Content PubMed PubMed Citation Articles by Eberhard, A. Articles by Augustin, H. G.

Heterogeneity of Angiogenesis and Blood Vessel Maturation in Human Tumors: Implications for Antiangiogenic Tumor Therapies¹

Cell Biology Laboratory, Department of Gynecology and Obstetrics [A. E., S. K., V. G., H. G. A.] and Department of Pathology [B. H.], University of Göttingen Medical School, 37075 Göttingen, Germany, and Department of Neuropathology, Erlangen-Nürnberg University Medical School, 91054 Erlangen, Germany [K. H. P.]

Microvessel density (MVD) counting techniques have been widely used to assess the vasculature in tumors. MVD counts assess the presence of blood vessels but do not give an indication of the degree of angiogenesis and the functional status of the tumor neovasculature. To analyze angiogenesis and the functional status of the tumor vascular bed, we have quantitated endothelial cell proliferation and the recruitment of pericytes in human tumors [glioblastomas (n = 30), renal cell carcinomas (n = 22), colon carcinomas (n = 18), mammary carcinomas (n = 24), lung carcinomas (n = 15), and prostate carcinomas (n = 19)]. These findings were compared to the physiological angiogenesis in the cyclic bovine ovarian corpus luteum. Tissue sections were examined applying double-labeling immunohistochemical techniques to detect proliferating endothelial cells and to colocalize endothelial cells and pericytes. The following parameters were quantitated: (a) MVD count; (b) proliferating capillary index (PCI); (c) proliferating tumor versus endothelial cell index; and (d) microvessel pericyte coverage index (MPI). Based on endothelial cell proliferation, angiogenesis was found to be present in all tumors with characteristic and significant differences between the tumor types (glioblastomas, PCI = 9.6 ± 6.1%; renal cell carcinomas, PCI = 9.4 ± 5.2%; colon carcinomas, PCI = 7.8 ± 5.2%; mammary carcinomas, PCI = 5.0 ± 4.8%; lung carcinomas, PCI = 2.6 ± 2.5%; prostate carcinomas, PCI = 2.0 ± 1.4%). There was a considerable degree of heterogeneity in the intensity of angiogenesis within each tumor group, as indicated by large standard deviations. Even in the most angiogenic tumors, angiogenesis was found to be 4 to 20 times less intense as compared with the physiological angiogenesis in the growing ovarian corpus rubrum (PCI = 40.6 ± 6.2%). Varying degrees of pericyte recruitment to the tumor microvasculature were determined in the different tumor types (glio-blastomas, MPI = 12.7 ± 7.9%; renal cell carcinomas, MPI = 17.9 ± 7.8%; colon carcinomas, MPI = 65.4 ± 10.5%; mammary carcinomas, MPI = 67.3 ± 14.2%; lung carcinomas, MPI = 40.8 ± 14.5%; prostate carcinomas, MPI = 29.6 ± 9.5%). The data demonstrate distinct quantitative variations in the intensity of angiogenesis in malignant human tumors. Furthermore, the varying degrees of pericyte recruitment indicate differences in the functional status of the tumor vasculature in different tumors that may reflect varying degrees of maturation of the tumor vascular bed.

This article has been cited by other articles:

				J. S. Brockenbrough, J. K. Morihara, S. E. Hawes, J. E. Stern, J. S. Rasey, L. W. Wiens, Q. Feng, and H. Vesselle Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-Small-cell Lung Carcinoma in Relation to Angiogenesis and Proliferation J. Histochem. Cytochem., November 1, 2009; 57(11): 1087 - 1097. [Abstract] [Full Text] [PDF]

				N. Song, Y. Huang, H. Shi, S. Yuan, Y. Ding, X. Song, Y. Fu, and Y. Luo Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1{alpha}/CXCR4 Axis Cancer Res., August 1, 2009; 69(15): 6057 - 6064. [Abstract] [Full Text] [PDF]

				M. M. Seavey, P. C. Maciag, N. Al-Rawi, D. Sewell, and Y. Paterson An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model J. Immunol., May 1, 2009; 182(9): 5537 - 5546. [Abstract] [Full Text] [PDF]

				S. Sauer, P. A. Erba, M. Petrini, A. Menrad, L. Giovannoni, C. Grana, B. Hirsch, L. Zardi, G. Paganelli, G. Mariani, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Blood, March 5, 2009; 113(10): 2265 - 2274. [Abstract] [Full Text] [PDF]

				Y. Pina, H. Boutrid, A. Schefler, S. Dubovy, W. Feuer, M.-E. Jockovich, and T. G. Murray Blood Vessel Maturation in Retinoblastoma Tumors: Spatial Distribution of Neovessels and Mature Vessels and Its Impact on Ocular Treatment Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1020 - 1024. [Abstract] [Full Text] [PDF]

				C. R. Bley, W. Jochum, K. Orlowski, P. Furmanova, V. Vuong, P. M.J. McSheehy, and M. Pruschy Role of the Microenvironment for Radiosensitization by Patupilone Clin. Cancer Res., February 15, 2009; 15(4): 1335 - 1342. [Abstract] [Full Text] [PDF]

				M. Belleri, D. Ribatti, M. Savio, L. A. Stivala, L. Forti, E. Tanghetti, P. Alessi, D. Coltrini, A. Bugatti, S. Mitola, et al. {alpha}v{beta}3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers Mol. Cancer Ther., December 1, 2008; 7(12): 3761 - 3770. [Abstract] [Full Text] [PDF]

				V. Goh, S. Halligan, F. Daley, D. M. Wellsted, T. Guenther, and C. I. Bartram Colorectal Tumor Vascularity: Quantitative Assessment with Multidetector CT--Do Tumor Perfusion Measurements Reflect Angiogenesis? Radiology, November 1, 2008; 249(2): 510 - 517. [Abstract] [Full Text] [PDF]

				G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill Tumour vascular disrupting agents: combating treatment resistance Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S12 - S20. [Abstract] [Full Text] [PDF]

				T. Martens, Y. Laabs, H. S. Gunther, D. Kemming, Z. Zhu, L. Witte, C. Hagel, M. Westphal, and K. Lamszus Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2 Clin. Cancer Res., September 1, 2008; 14(17): 5447 - 5458. [Abstract] [Full Text] [PDF]

				J. A. Blansfield, D. Caragacianu, H. R. Alexander III, M. A. Tangrea, S. Y. Morita, D. Lorang, P. Schafer, G. Muller, D. Stirling, R. E. Royal, et al. Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy Clin. Cancer Res., January 1, 2008; 14(1): 270 - 280. [Abstract] [Full Text] [PDF]

				B. M. Fenton and S. F. Paoni The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature Cancer Res., October 15, 2007; 67(20): 9921 - 9928. [Abstract] [Full Text] [PDF]

				D. Hoogewijs, N. B. Terwilliger, K. A. Webster, J. A. Powell-Coffman, S. Tokishita, H. Yamagata, T. Hankeln, T. Burmester, K. T. Rytkonen, M. Nikinmaa, et al. From critters to cancers: bridging comparative and clinical research on oxygen sensing, HIF signaling, and adaptations towards hypoxia Integr. Comp. Biol., October 1, 2007; 47(4): 552 - 577. [Abstract] [Full Text] [PDF]

				W. Wu, M. S. O'Reilly, R. R. Langley, R. Z. Tsan, C. H. Baker, N. Bekele, X. M. Tang, A. Onn, I. J. Fidler, and R. S. Herbst Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice Mol. Cancer Ther., October 1, 2007; 6(10): 2652 - 2663. [Abstract] [Full Text] [PDF]

				B. Sennino, B. L. Falcon, D. McCauley, T. Le, T. McCauley, J. C. Kurz, A. Haskell, D. M. Epstein, and D. M. McDonald Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Cancer Res., August 1, 2007; 67(15): 7358 - 7367. [Abstract] [Full Text] [PDF]

				H. Hung Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts Mol. Cancer Ther., August 1, 2007; 6(8): 2149 - 2157. [Abstract] [Full Text] [PDF]

				M.-E. Jockovich, M. L. Bajenaru, Y. Pina, F. Suarez, W. Feuer, M. E. Fini, and T. G. Murray Retinoblastoma Tumor Vessel Maturation Impacts Efficacy of Vessel Targeting in the LHBETATAG Mouse Model Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2476 - 2482. [Abstract] [Full Text] [PDF]

				R. R. Langley and I. J. Fidler Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis Endocr. Rev., May 1, 2007; 28(3): 297 - 321. [Abstract] [Full Text] [PDF]

				E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows Haematologica, May 1, 2007; 92(5): 597 - 604. [Abstract] [Full Text] [PDF]

				Y. Cao, P. Sonveaux, S. Liu, Y. Zhao, J. Mi, B. M. Clary, C.-Y. Li, C. D. Kontos, and M. W. Dewhirst Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth Cancer Res., April 15, 2007; 67(8): 3835 - 3844. [Abstract] [Full Text] [PDF]

				M. A. Rosen and M. D. Schnall Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 770s - 776s. [Abstract] [Full Text] [PDF]

				X. Yao, C.-N. Qian, Z.-F. Zhang, M.-H. Tan, E. J. Kort, X. J. Yang, J. H. Resau, and B. T. Teh Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications Clin. Cancer Res., January 1, 2007; 13(1): 161 - 169. [Abstract] [Full Text] [PDF]

				Y. Takahashi, Y. Akishima-Fukasawa, N. Kobayashi, T. Sano, T. Kosuge, Y. Nimura, Y. Kanai, and N. Hiraoka Prognostic Value of Tumor Architecture, Tumor-Associated Vascular Characteristics, and Expression of Angiogenic Molecules in Pancreatic Endocrine Tumors Clin. Cancer Res., January 1, 2007; 13(1): 187 - 196. [Abstract] [Full Text] [PDF]

				A. P. Hall Review of the Pericyte during Angiogenesis and its Role in Cancer and Diabetic Retinopathy Toxicol Pathol, October 1, 2006; 34(6): 763 - 775. [Full Text] [PDF]

				N. S. Patel, M. S. Dobbie, M. Rochester, G. Steers, R. Poulsom, K. Le Monnier, D. W. Cranston, J.-L. Li, and A. L. Harris Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer. Clin. Cancer Res., August 15, 2006; 12(16): 4836 - 4844. [Abstract] [Full Text] [PDF]

				S.-J. Kim, H. Uehara, S. Yazici, J. E. Busby, T. Nakamura, J. He, M. Maya, C. Logothetis, P. Mathew, X. Wang, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst, June 7, 2006; 98(11): 783 - 793. [Abstract] [Full Text] [PDF]

				P. Martinive, J. De Wever, C. Bouzin, C. Baudelet, P. Sonveaux, V. Gregoire, B. Gallez, and O. Feron Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol. Cancer Ther., June 1, 2006; 5(6): 1620 - 1627. [Abstract] [Full Text] [PDF]

				S. Dell, S. Peters, P. Muther, N. Kociok, and A. M. Joussen The Role of PDGF Receptor Inhibitors and PI3-Kinase Signaling in the Pathogenesis of Corneal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1928 - 1937. [Abstract] [Full Text] [PDF]

				J. H. Wang, P. Q. Min, P. J. Wang, W. X. Cheng, X. H. Zhang, Y. Wang, X. H. Zhao, and X. Q. Mao Dynamic CT Evaluation of Tumor Vascularity in Renal Cell Carcinoma. Am. J. Roentgenol., May 1, 2006; 186(5): 1423 - 1430. [Abstract] [Full Text] [PDF]

				I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res., March 15, 2006; 66(6): 3303 - 3309. [Abstract] [Full Text] [PDF]

				D. R. Yance Jr and S. M. Sagar Targeting Angiogenesis With Integrative Cancer Therapies Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF]

				J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al. Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas J. Nucl. Med., March 1, 2006; 47(3): 419 - 425. [Abstract] [Full Text] [PDF]

				K. Yokoi, T. Sasaki, C. D. Bucana, D. Fan, C. H. Baker, Y. Kitadai, T. Kuwai, J. L. Abbruzzese, and I. J. Fidler Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model Cancer Res., November 15, 2005; 65(22): 10371 - 10380. [Abstract] [Full Text] [PDF]

				R. G. Bagley, W. Weber, C. Rouleau, and B. A. Teicher Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy Cancer Res., November 1, 2005; 65(21): 9741 - 9750. [Abstract] [Full Text] [PDF]

				E. van der Veer, Z. Nong, C. O'Neil, B. Urquhart, D. Freeman, and J. G. Pickering Pre-B-Cell Colony-Enhancing Factor Regulates NAD+-Dependent Protein Deacetylase Activity and Promotes Vascular Smooth Muscle Cell Maturation Circ. Res., July 8, 2005; 97(1): 25 - 34. [Abstract] [Full Text] [PDF]

				E. W. Newcomb, M. A. Ali, T. Schnee, L. Lan, Y. Lukyanov, M. Fowkes, D. C. Miller, and D. Zagzag Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1{alpha} expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy Neuro-oncol, July 1, 2005; 7(3): 225 - 235. [Abstract] [PDF]

				P. H. Thaker, S. Yazici, M. B. Nilsson, K. Yokoi, R. Z. Tsan, J. He, S.-J. Kim, I. J. Fidler, and A. K. Sood Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors Clin. Cancer Res., July 1, 2005; 11(13): 4923 - 4933. [Abstract] [Full Text] [PDF]

				P.-P. Zheng, W. C. Hop, P. A.E. Sillevis Smitt, M. J. van den Bent, C. J.J. Avezaat, T. M. Luider, and J. M. Kros Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma Clin. Cancer Res., June 15, 2005; 11(12): 4388 - 4392. [Abstract] [Full Text] [PDF]

				S. Wada, T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya, and H. Tahara Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2 Cancer Res., June 1, 2005; 65(11): 4939 - 4946. [Abstract] [Full Text] [PDF]

				S.-J. Kim, H. Uehara, S. Yazici, J. He, R. R. Langley, P. Mathew, D. Fan, and I. J. Fidler Modulation of Bone Microenvironment with Zoledronate Enhances the Therapeutic Effects of STI571 and Paclitaxel against Experimental Bone Metastasis of Human Prostate Cancer Cancer Res., May 1, 2005; 65(9): 3707 - 3715. [Abstract] [Full Text] [PDF]

				K. Yokoi, P. H. Thaker, S. Yazici, R. R. Rebhun, D.-H. Nam, J. He, S.-J. Kim, J. L. Abbruzzese, S. R. Hamilton, and I. J. Fidler Dual Inhibition of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Phosphorylation by AEE788 Reduces Growth and Metastasis of Human Colon Carcinoma in an Orthotopic Nude Mouse Model Cancer Res., May 1, 2005; 65(9): 3716 - 3725. [Abstract] [Full Text] [PDF]

				X.-F. Zhu, B.-F. Xie, J.-M. Zhou, G.-K. Feng, Z.-C. Liu, X.-Y. Wei, F.-X. Zhang, M.-F. Liu, and Y.-X. Zeng Blockade of Vascular Endothelial Growth Factor Receptor Signal Pathway and Antitumor Activity of ON-III (2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a Component from Chinese Herbal Medicine Mol. Pharmacol., May 1, 2005; 67(5): 1444 - 1450. [Abstract] [Full Text] [PDF]

				L. M. Ellis Challenges in Translating Antiangiogenic Therapy from Bench to Bedside Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 74 - 77. [Full Text] [PDF]

				K Gupta and J Zhang Angiogenesis: a curse or cure? Postgrad. Med. J., April 1, 2005; 81(954): 236 - 242. [Abstract] [Full Text] [PDF]

				M. R. Machein, A. Knedla, R. Knoth, S. Wagner, E. Neuschl, and K. H. Plate Angiopoietin-1 Promotes Tumor Angiogenesis in a Rat Glioma Model Am. J. Pathol., November 1, 2004; 165(5): 1557 - 1570. [Abstract] [Full Text] [PDF]

				D. W. J. van der Schaft, R. E. B. Seftor, E. A. Seftor, A. R. Hess, L. M. Gruman, D. A. Kirschmann, Y. Yokoyama, A. W. Griffioen, and M. J. C. Hendrix Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells J Natl Cancer Inst, October 6, 2004; 96(19): 1473 - 1477. [Abstract] [Full Text] [PDF]

				G. K. Owens, M. S. Kumar, and B. R. Wamhoff Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease Physiol Rev, July 1, 2004; 84(3): 767 - 801. [Abstract] [Full Text] [PDF]

				S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He, R. Tsan, D. Fan, J. J. Killion, and I. J. Fidler Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice Cancer Res., June 15, 2004; 64(12): 4201 - 4208. [Abstract] [Full Text] [PDF]

				A. M. Ab' Saber, L. M. Massoni Neto, C. P. Bianchi, B. B. Ctenas, E. R. Parra, E. M. Eher, J. C. Pereira, T. Takagaki, N. H. Yamaguchi, and V. L. Capelozzi Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas Ann. Thorac. Surg., June 1, 2004; 77(6): 1883 - 1890. [Abstract] [Full Text] [PDF]

				P.-P. Zheng, A. M. Sieuwerts, T. M. Luider, M. van der Weiden, P. A.E. Sillevis-Smitt, and J. M. Kros Differential Expression of Splicing Variants of the Human Caldesmon Gene (CALD1) in Glioma Neovascularization versus Normal Brain Microvasculature Am. J. Pathol., June 1, 2004; 164(6): 2217 - 2228. [Abstract] [Full Text] [PDF]

				G. A. Christoforidis, A. Kangarlu, A. M. Abduljalil, P. Schmalbrock, A. Chaudhry, A. Yates, and D. W. Chakeres Susceptibility-Based Imaging of Glioblastoma Microvascularity at 8 T: Correlation of MR Imaging and Postmortem Pathology AJNR Am. J. Neuroradiol., May 1, 2004; 25(5): 756 - 760. [Abstract] [Full Text] [PDF]

				B. R. Shepherd, H. Y.S. Chen, C. M. Smith, G. Gruionu, S. K. Williams, and J. B. Hoying Rapid Perfusion and Network Remodeling in a Microvascular Construct After Implantation Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 898 - 904. [Abstract] [Full Text]

				P. Dobrzanski, K. Hunter, S. Jones-Bolin, H. Chang, C. Robinson, S. Pritchard, H. Zhao, and B. Ruggeri Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist Cancer Res., February 1, 2004; 64(3): 910 - 919. [Abstract] [Full Text] [PDF]

				H G Augustin Translating angiogenesis research into the clinic: the challenges ahead Br. J. Radiol., December 1, 2003; 76(suppl_1): S3 - S10. [Abstract] [Full Text] [PDF]

				G M Tozer Measuring tumour vascular response to antivascular and antiangiogenic drugs Br. J. Radiol., December 1, 2003; 76(suppl_1): S23 - S35. [Abstract] [Full Text] [PDF]

				P. Baluk, S. Morikawa, A. Haskell, M. Mancuso, and D. M. McDonald Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors Am. J. Pathol., November 1, 2003; 163(5): 1801 - 1815. [Abstract] [Full Text] [PDF]

				G. Bocci, G. Francia, S. Man, J. Lawler, and R. S. Kerbel Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy PNAS, October 28, 2003; 100(22): 12917 - 12922. [Abstract] [Full Text] [PDF]

				B. Ruggeri, J. Singh, D. Gingrich, T. Angeles, M. Albom, H. Chang, C. Robinson, K. Hunter, P. Dobrzanski, S. Jones-Bolin, et al. CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models Cancer Res., September 15, 2003; 63(18): 5978 - 5991. [Abstract] [Full Text] [PDF]

				V. Kostourou, S. P. Robinson, G. St. J. Whitley, and J. R. Griffiths Effects of Overexpression of Dimethylarginine Dimethylaminohydrolase on Tumor Angiogenesis Assessed by Susceptibility Magnetic Resonance Imaging Cancer Res., August 15, 2003; 63(16): 4960 - 4966. [Abstract] [Full Text] [PDF]

				O. Stoeltzing, S. A. Ahmad, W. Liu, M. F. McCarty, J. S. Wey, A. A. Parikh, F. Fan, N. Reinmuth, M. Kawaguchi, C. D. Bucana, et al. Angiopoietin-1 Inhibits Vascular Permeability, Angiogenesis, and Growth of Hepatic Colon Cancer Tumors Cancer Res., June 15, 2003; 63(12): 3370 - 3377. [Abstract] [Full Text] [PDF]

				P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]

				R. Giavazzi, B. Sennino, D. Coltrini, A. Garofalo, R. Dossi, R. Ronca, M. P. M. Tosatti, and M. Presta Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis Am. J. Pathol., June 1, 2003; 162(6): 1913 - 1926. [Abstract] [Full Text] [PDF]

				N. Reinmuth, W. Liu, S. A. Ahmad, F. Fan, O. Stoeltzing, A. A. Parikh, C. D. Bucana, G. E. Gallick, M. A. Nickols, W. F. Westlin, et al. {alpha}v{beta}3 Integrin Antagonist S247 Decreases Colon Cancer Metastasis and Angiogenesis and Improves Survival in Mice Cancer Res., May 1, 2003; 63(9): 2079 - 2087. [Abstract] [Full Text] [PDF]

				K. D. Miller, C. J. Sweeney, and G. W. Sledge The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era Ann. Onc., January 1, 2003; 14(1): 20 - 28. [Abstract] [Full Text] [PDF]

				M. S. Gee, W. N. Procopio, S. Makonnen, M. D. Feldman, N. M. Yeilding, and W. M. F. Lee Tumor Vessel Development and Maturation Impose Limits on the Effectiveness of Anti-Vascular Therapy Am. J. Pathol., January 1, 2003; 162(1): 183 - 193. [Abstract] [Full Text] [PDF]

				C Cursiefen, C Hofmann-Rummelt, M Kuchle, and U Schlotzer-Schrehardt Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation Br J Ophthalmol, January 1, 2003; 87(1): 101 - 106. [Abstract] [Full Text] [PDF]

				P. D. Davis, G. J. Dougherty, D. C. Blakey, S. M. Galbraith, G. M. Tozer, A. L. Holder, M. A. Naylor, J. Nolan, M. R. L. Stratford, D. J. Chaplin, et al. ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature Cancer Res., December 15, 2002; 62(24): 7247 - 7253. [Abstract] [Full Text] [PDF]

				G. Bocci, K. C. Nicolaou, and R. S. Kerbel Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival in Vitro Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs Cancer Res., December 1, 2002; 62(23): 6938 - 6943. [Abstract] [Full Text] [PDF]

				W. W. Spurbeck, C. Y. C. Ng, T. S. Strom, E. F. Vanin, and A. M. Davidoff Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model Blood, October 16, 2002; 100(9): 3361 - 3368. [Abstract] [Full Text] [PDF]

				G. A. Christoforidis, J. C. Grecula, H. B. Newton, A. Kangarlu, A. M. Abduljalil, P. Schmalbrock, and D. W Chakeres Visualization of Microvascularity in Glioblastoma Multiforme With 8-T High-Spatial-Resolution MR Imaging AJNR Am. J. Neuroradiol., October 1, 2002; 23(9): 1553 - 1556. [Abstract] [Full Text] [PDF]

				M. Hangai, N. Kitaya, J. Xu, C. K. Chan, J. J. Kim, Z. Werb, S. J. Ryan, and P. C. Brooks Matrix Metalloproteinase-9-Dependent Exposure of a Cryptic Migratory Control Site in Collagen is Required before Retinal Angiogenesis Am. J. Pathol., October 1, 2002; 161(4): 1429 - 1437. [Abstract] [Full Text] [PDF]

				F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]

				L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]

				S. Man, G. Bocci, G. Francia, S. K. Green, S. Jothy, D. Hanahan, P. Bohlen, D. J. Hicklin, G. Bergers, and R. S. Kerbel Antitumor Effects in Mice of Low-dose (Metronomic) Cyclophosphamide Administered Continuously through the Drinking Water Cancer Res., May 1, 2002; 62(10): 2731 - 2735. [Abstract] [Full Text] [PDF]

				A. Adini, T. Kornaga, F. Firoozbakht, and L. E. Benjamin Placental Growth Factor Is a Survival Factor for Tumor Endothelial Cells and Macrophages Cancer Res., May 1, 2002; 62(10): 2749 - 2752. [Abstract] [Full Text] [PDF]

				A. Giatromanolaki, E. Sivridis, G. Minopoulos, A. Polychronidis, C. Manolas, C. Simopoulos, and M. I. Koukourakis Differential Assessment of Vascular Survival Ability and Tumor Angiogenic Activity in Colorectal Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1185 - 1191. [Abstract] [Full Text] [PDF]

				S. Morikawa, P. Baluk, T. Kaidoh, A. Haskell, R. K. Jain, and D. M. McDonald Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors Am. J. Pathol., March 1, 2002; 160(3): 985 - 1000. [Abstract] [Full Text] [PDF]

				J. C. Lee, D. C. Kim, M. S. Gee, H. M. Saunders, C. M. Sehgal, M. D. Feldman, S. R. Ross, and W. M. F. Lee Interleukin-12 Inhibits Angiogenesis and Growth of Transplanted but not in Situ Mouse Mammary Tumor Virus-induced Mammary Carcinomas Cancer Res., February 1, 2002; 62(3): 747 - 755. [Abstract] [Full Text] [PDF]

				R. S. Kerbel, G. Klement, K. I. Pritchard, and B. Kamen Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic Ann. Onc., January 19, 2002; 13(1): 12 - 15. [Full Text] [PDF]

				A. K. Sood, M. S. Fletcher, and M. J. C. Hendrix The Embryonic-Like Properties of Aggressive Human Tumor Cells Reproductive Sciences, January 1, 2002; 9(1): 2 - 9. [Abstract] [PDF]

				S. Franco, I. Segura, H. H. Riese, and M. A. Blasco Decreased B16F10 Melanoma Growth and Impaired Vascularization in Telomerase-deficient Mice with Critically Short Telomeres Cancer Res., January 1, 2002; 62(2): 552 - 559. [Abstract] [Full Text] [PDF]

				G. Klement, P. Huang, B. Mayer, S. K. Green, S. Man, P. Bohlen, D. Hicklin, and R. S. Kerbel Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts Clin. Cancer Res., January 1, 2002; 8(1): 221 - 232. [Abstract] [Full Text] [PDF]

				A. Abramsson, O. Berlin, H. Papayan, D. Paulin, M. Shani, and C. Betsholtz Analysis of Mural Cell Recruitment to Tumor Vessels Circulation, January 1, 2002; 105(1): 112 - 117. [Abstract] [Full Text] [PDF]

				Y. Song, L. Wu, J. C. Shryock, and L. Belardinelli Selective Attenuation of Isoproterenol-Stimulated Arrhythmic Activity by a Partial Agonist of Adenosine A1 Receptor Circulation, January 1, 2002; 105(1): 118 - 123. [Abstract] [Full Text] [PDF]

				C. Mundhenke, J. P. Thomas, G. Wilding, F. T. Lee, F. Kelzc, R. Chappell, R. Neider, L. A. Sebree, and A. Friedl Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin Clin. Cancer Res., November 1, 2001; 7(11): 3366 - 3374. [Abstract] [Full Text] [PDF]

				H. G. Augustin Tubes, Branches, and Pillars: The Many Ways of Forming a New Vasculature Circ. Res., October 12, 2001; 89(8): 645 - 647. [Full Text] [PDF]

				A R Padhani and M Neeman Challenges for imaging angiogenesis Br. J. Radiol., October 1, 2001; 74(886): 886 - 890. [Full Text] [PDF]

				Y. Dor, R. Porat, and E. Keshet Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1367 - C1374. [Abstract] [Full Text] [PDF]

				A. K. Sood, E. A. Seftor, M. S. Fletcher, L. M. G. Gardner, P. M. Heidger, R. E. Buller, R. E. B. Seftor, and M. J. C. Hendrix Molecular Determinants of Ovarian Cancer Plasticity Am. J. Pathol., April 1, 2001; 158(4): 1279 - 1288. [Abstract] [Full Text] [PDF]

				D. J. Brat and E. G. Van Meir Glomeruloid Microvascular Proliferation Orchestrated by VPF/VEGF : A New World of Angiogenesis Research Am. J. Pathol., March 1, 2001; 158(3): 789 - 796. [Full Text] [PDF]

				K. D. Miller, C. J. Sweeney, and G. W. Sledge Jr Redefining the Target: Chemotherapeutics as Antiangiogenics J. Clin. Oncol., February 15, 2001; 19(4): 1195 - 1206. [Abstract] [Full Text] [PDF]

				R. M. Shaheen, W. W. Tseng, D. W. Davis, W. Liu, N. Reinmuth, R. Vellagas, A. A. Wieczorek, Y. Ogura, D. J. McConkey, K. E. Drazan, et al. Tyrosine Kinase Inhibition of Multiple Angiogenic Growth Factor Receptors Improves Survival in Mice Bearing Colon Cancer Liver Metastases by Inhibition of Endothelial Cell Survival Mechanisms Cancer Res., February 1, 2001; 61(4): 1464 - 1468. [Abstract] [Full Text]

				D. H. Gorski and K. Walsh The Role of Homeobox Genes in Vascular Remodeling and Angiogenesis Circ. Res., November 10, 2000; 87(10): 865 - 872. [Abstract] [Full Text] [PDF]